Introducing Formulite®
Addressing the challenge of poor oral bioavailability
Poor aqueous solubility is one of the most persistent challenges in oral drug development, with an estimated 70–90% of drug candidates being poorly soluble. The challenge is particularly relevant for compounds classified as BCS Class II and IV, where limited solubility can restrict dissolution, absorption and ultimately oral exposure.
Formulite® was developed to address this challenge by stabilizing poorly soluble drug compounds in an amorphous state. By improving apparent solubility and accelerate dissolution, the platform supports the potential for improved absorption and oral bioavailability.
Key benefits of Formulite® for oral drug development
Formulite® combines improved drug performance with efficient formulation and more sustainable drug product development and manufacturing.
Enhanced bioavailability
Improves dissolution and supports the potential for improved oral exposure by stabilizing poorly soluble drug compounds in an amorphous state.
Optimized pill size
Enables high drug loading, with the potential for smaller tablets or capsules, lower excipient burden and improved patient convenience.
Eco-friendly manufacturing
Supports efficient manufacturing using conventional pharmaceutical processes, with high process yield and limited solvent use.
Available for feasibility and development programs
Formulite® is a partner-ready formulation platform designed for oral drug product development.
The platform can be applied to new drug candidates, approved drug compounds and lifecycle management opportunities where improved product performance may create clinical, commercial or patient value.
